Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV

For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com

Key Inclusion Criteria:

- Subjects must be able to understand and agree to comply with the prescribed dosing
regimens and procedures, report for regularly scheduled study visits, and reliably
communicate with study personnel about adverse events and concomitant medications

- Subjects chronically infected with hepatitis C virus (HCV) genotype 3

- Subjects who are HCV treatment-naive

- Subjects who are HCV treatment-experienced (previous exposure to non-structural 5A
inhibitors is prohibited)

- HCV RNA ≥10,000 IU/mL at screening

Key Exclusion Criteria:

- HCV Genotypes other than genotype-3 infection; mixed genotype infections are not
permitted

- Liver or any other organ transplant (including hematopoietic stem cell transplants)
other than cornea and hair

- Current or known history of cancer (except in situ carcinoma of the cervix or
adequately treated basal or squamous cell carcinoma of the skin) within 5 years prior
to screening

- Documented or suspected hepatocellular carcinoma, as evidenced by previously obtained
imaging studies or liver biopsy (or on a screening imaging study/liver biopsy if this
was performed)

- Evidence of decompensated liver disease including, but not limited to, radiologic
criteria, a history or presence of ascites, bleeding varices, or hepatic
encephalopathy